- New pivotal data demonstrate clinical benefit of Roche’s glofitamab, a potential first-in-class bispecific antibody for people with aggressive lymphoma
- Roche’s Polivy combination approved by European Commission for people with previously untreated diffuse large B-cell lymphoma
- Roche développe des tests PCR de détection du virus de la variole simienne
- Roche entwickelt einzigartige PCR-Tests zur Erkennung des Affenpockenvirus
- Roche develops unique PCR tests to detect the monkeypox virus
- Data at the 2022 ASCO Annual Meeting highlight Roche’s continued commitment to innovation in oncology and personalised healthcare
- Roche enters partnership with the Global Fund to support low- and middle-income countries in strengthening critical diagnostics infrastructure
- [Ad hoc announcement pursuant to Art. 53 LR] Roche reports interim results for phase III SKYSCRAPER-01 study in PD-L1-high metastatic non-small cell lung cancer
- Roche pledges to extend commitment to the World Federation of Hemophilia Humanitarian Aid Program to 2028
- New three-year data for Roche’s Evrysdi (risdiplam) show long-term improvements in survival and motor milestones in babies with Type 1 spinal muscular atrophy (SMA)
More ▼
Key statistics
On Friday, Roche Holding AG (ROG:SWX) closed at 329.80, 6.82% above its 52-week low of 308.75, set on Jun 03, 2021.
52-week range
Markit short selling activity
Open | 333.00 |
---|---|
High | 333.40 |
Low | 327.85 |
Bid | -- |
Offer | -- |
Previous close | 333.00 |
Average volume | 1.36m |
---|---|
Shares outstanding | 809.25m |
Free float | 728.90m |
P/E (TTM) | 20.37 |
Market cap | 271.08bn CHF |
EPS (TTM) | 16.19 CHF |
Annual div (ADY) | 9.30 CHF |
---|---|
Annual div yield (ADY) | 2.82% |
Div ex-date | Mar 17 2022 |
Div pay-date | Mar 21 2022 |
Data delayed at least 15 minutes, as of May 27 2022 16:39 BST.
More ▼